<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mitral valve prolapse: Clinical manifestations and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mitral valve prolapse: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mitral valve prolapse: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maurice Enriquez-Sarano, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine M Otto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H28356697"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mitral valve prolapse (MVP) is a common disease of the mitral valve. The clinical and anatomic characteristics of patients with MVP are heterogeneous. Although most patients with MVP have mild, trivial, or no mitral regurgitation (MR) [<a href="#rid1">1</a>], MVP is the most common cause of primary moderate or severe MR requiring intervention in resource-abundant countries [<a href="#rid2">2,3</a>]. In resource-limited countries, rheumatic mitral valve disease is more common. (See  <a class="medical medical_review" href="/d/html/13612.html" rel="external">"Clinical manifestations and diagnosis of rheumatic heart disease", section on 'Mitral regurgitation'</a>.)</p><p>The definition, classification, pathophysiology, and diagnosis of MVP will be reviewed here.</p><p>Other aspects of MVP are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8169.html" rel="external">"Mitral valve prolapse: Overview of complications and their management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8162.html" rel="external">"Natural history of chronic mitral regurgitation caused by mitral valve prolapse and flail mitral leaflet"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8132.html" rel="external">"Chronic primary mitral regurgitation: General management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8170.html" rel="external">"Acute mitral regurgitation in adults"</a>.)</p><p></p><p class="headingAnchor" id="H783465924"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>MVP is a cause of primary mitral regurgitation (MR; caused by disease of one or more valve components, including leaflets, chordae tendineae, papillary muscles, or annulus) rather than secondary/functional MR (caused by disease of the left ventricle [LV]) [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation", section on 'Identifying the cause of MR'</a>.)</p><p>MVP is diagnosed clinically based on echocardiography showing diffuse redundancy and thickening of the mitral valve leaflets with systolic billowing of one or both leaflets ≥2 mm above the plane of the mitral annulus into the left atrium in a long-axis view (parasternal or apical three-chamber)  (<a class="graphic graphic_diagnosticimage graphicRef83594" href="/d/graphic/83594.html" rel="external">image 1</a>) [<a href="#rid6">6</a>], with or without associated MR. Echocardiographic criteria for MVP are described further below. (See <a class="local">'Imaging definition of MVP'</a> below.)</p><p class="headingAnchor" id="H28356738"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Using the currently accepted definition of MVP, its prevalence in the general population is estimated to be 0.6 to 3 percent [<a href="#rid7">7-10</a>]. The Framingham Heart Study reported an overall prevalence of 2.4 percent [<a href="#rid7">7</a>]. Individuals with classic MVP (leaflet thickness ≥5 mm; 1.3 percent) and nonclassic MVP (leaflet thickness &lt;5 mm; 1.1 percent) had similar age and sex distributions. In another population-based study (Cardia), the prevalence of MVP in 4136 young adults was only 0.6 percent [<a href="#rid8">8</a>]. In a Canadian study of 972 patients, MVP prevalence was similar in three ethnic groups (2.7 percent in South Asian, 3.1 percent in European, and 2.2 percent in Chinese) [<a href="#rid9">9</a>]. MVP patients were leaner and had a greater degree of mitral regurgitation (MR) than the general population [<a href="#rid7">7,8</a>]. Because MVP is a progressive lesion, anatomically [<a href="#rid11">11</a>] and physiologically in terms of MR severity [<a href="#rid12">12</a>], these prevalence differences are generally interpreted as age-related, with higher prevalence in older cohorts.</p><p>MVP may be slightly more common in females than in males. In the Framingham study, there was a nonsignificant trend toward a female preponderance among those with MVP (59.5 versus 52.7 percent in those without MVP) [<a href="#rid7">7</a>]; in the larger Olmsted county study, 64 percent of individuals with MVP were females [<a href="#rid13">13</a>].</p><p>Reports published early in the development of echocardiography suggested high MVP prevalence, 4 to 10 percent, and even close to 20 percent in selected populations [<a href="#rid14">14-16</a>]. These early reports are now considered inaccurate because echocardiographic criteria for diagnosis were not yet fully developed and lacked specificity.</p><p class="headingAnchor" id="H3358994883"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>MVP is classified as either primary (caused by abnormal mitral leaflet tissue in the absence of an identifiable connective tissue disease; may be sporadic or familial) or secondary (associated with an identifiable disorder such as Marfan syndrome or congenital heart disease)  (<a class="graphic graphic_table graphicRef83655" href="/d/graphic/83655.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H454752131"><span class="h2">Primary MVP</span><span class="headingEndMark"> — </span>Primary MVP can be sporadic or familial. It may present as an isolated lesion or accompanied by cardiac and/or extracardiac findings.</p><p class="headingAnchor" id="H1914425471"><span class="h3">Sporadic or familial</span><span class="headingEndMark"> — </span>While most cases of primary MVP are sporadic, familial cases of classic (diffuse myxomatous) MVP also occur [<a href="#rid17">17-21</a>]. Multiple genetic loci for MVP have been identified [<a href="#rid22">22,23</a>]. A large genome-wide association study identified 16 loci associated with MVP; candidate genes for MVP included genes linked to transforming-growth-factor beta (TGF-β), cardiomyopathy, or cytoskeletal physiology [<a href="#rid23">23</a>]. This genetic heterogeneity matches the morphologic and clinical heterogeneity of MVP.</p><p>The most common reported transmission pattern for MVP is autosomal dominant with incomplete penetrance [<a href="#rid22">22</a>]. The prevalence in first-degree relatives is relatively high, ranging from 30 to 50 percent [<a href="#rid24">24,25</a>].</p><p class="bulletIndent1">A less common X-linked recessive form seems to be related to filamin A mutations, and results in a rare form of multivalvular myxomatous degeneration (X-linked myxomatous valvular dystrophy) [<a href="#rid26">26,27</a>]. In affected males, this disease is characterized by myxomatous degeneration of the mitral valve frequently associated with aortic valve degeneration. Female carriers can also exhibit valvular degeneration, but this is usually less severe.</p><p></p><p class="headingAnchor" id="H1758245023"><span class="h3">Concomitant valve disease</span><span class="headingEndMark"> — </span>Some patients with MVP present with a phenotype associated with concomitant valve disease, including the following conditions:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tricuspid valve prolapse</strong> – Small studies suggest that MVP is commonly associated with tricuspid valve prolapse (TVP). In a study of 263 patients with MVP (128 with single-leaflet MVP and 135 with bileaflet MVP), 24 percent of patients with single-leaflet MVP and 47 percent of those with bileaflet MVP had cardiovascular magnetic resonance (CMR) criteria for TVP [<a href="#rid28">28</a>]. None of 202 patients with primary mitral regurgitation (MR) without MVP had TVP. Patients with TVP were more likely to have severe MR (38.3 versus 18.9 percent) and moderate or severe tricuspid regurgitation (23.4 versus 6.2 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bicuspid aortic valve</strong> – In a study of a community-based echocardiographic database including 363,795 patients, the prevalence of MVP among individuals with bicuspid aortic valves (BAV) was similar to the prevalence of MVP among individuals with tricuspid aortic valves (TAV; 2.7 versus 3.4 percent) [<a href="#rid29">29</a>]. While posterior mitral leaflet prolapse (PML) was the most common MVP phenotype for both BAV and TAV (38 versus 43 percent), anterior mitral leaflet (AML) prolapse was more common with BAV than with TAV (31 versus 15 percent). A subset (24 percent) of individuals with AML prolapse and BAV had large-AML prolapse (AML:PML length ratio ≥3.1), with most of this subset exhibiting giant-AML prolapse with a diminutive PML. At least moderate BAV regurgitation was identified in 61 percent of patients with giant-AML prolapse.</p><p></p><p class="headingAnchor" id="H1659956329"><span class="h3">Nonsyndromic or syndromic</span><span class="headingEndMark"> — </span>Primary MVP is classified as nonsyndromic when extracardiac manifestations are absent and syndromic when extracardiac manifestations are present. Additional extracardiac manifestations include von Willebrand syndrome [<a href="#rid18">18</a>] (eg, thoracic skeletal abnormalities such as pectus excavatum [<a href="#rid17">17,30</a>]) and hypomastia [<a href="#rid31">31</a>]. The latter two associations suggest that MVP may be related to a linked mesenchymal dysplasia, although hypomastia may also be a simple reflection of patients’ lean body habitus.</p><p></p><p class="headingAnchor" id="H841047361"><span class="h3">Morphology of primary MVP</span><span class="headingEndMark"> — </span>While primary MVP presents with a great diversity of lesions, the macro-alterations are often categorized as either diffuse myxomatous or fibroelastic deficiency. It is important to distinguish between these forms, as the complexity of surgical repair increases with the extent of mitral valve involvement by myxomatous degeneration.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse myxomatous</strong> – At one end of the spectrum is diffuse myxomatous (also known as Barlow disease or classic) MVP, characterized by markedly thickened (≥5 mm) and diffusely redundant myxomatous leaflet tissue with prolapse of most of the segments of both leaflets, severe mitral annular enlargement, and elongated (rarely ruptured) chords  (<a class="graphic graphic_figure graphicRef83595" href="/d/graphic/83595.html" rel="external">figure 1</a> and <a class="graphic graphic_movie graphicRef83604 graphicRef83605" href="/d/graphic/83604.html" rel="external">movie 1A-B</a>) [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1">A subset of patients with classic MVP have mitral annular disjunction, an abnormality of the mitral annulus fibrosus resulting in a systolic gap between the insertion of the posterior mitral leaflet and the basal inferolateral myocardium  (<a class="graphic graphic_movie graphicRef83606" href="/d/graphic/83606.html" rel="external">movie 2</a>). This disjunction commonly occurs in patients with advanced classic disease [<a href="#rid33">33</a>] and is associated with progressive development of ventricular arrhythmias and LV dilation [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/8169.html" rel="external">"Mitral valve prolapse: Overview of complications and their management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibroelastic deficiency</strong> – At the other end of the spectrum is fibroelastic deficiency (also known as nonclassic), first described by Carpentier [<a href="#rid35">35</a>], which can be seen in up to 40 percent of patients requiring mitral valve repair. It usually affects individuals over the age of 60 and is characterized by involvement of a single segment (most commonly P2 scallop), with thin (&lt;5 mm thickness) and somewhat redundant leaflets, ruptured chords, and mild mitral annular enlargement  (<a class="graphic graphic_figure graphicRef83595" href="/d/graphic/83595.html" rel="external">figure 1</a> and <a class="graphic graphic_movie graphicRef83602 graphicRef83603" href="/d/graphic/83602.html" rel="external">movie 3A-B</a>). The flail segment is thickened and myxomatous in a very localized manner. This MVP type is often associated with cleft-like indentations separating posterior mitral scallops [<a href="#rid36">36</a>] that may affect the quality of mitral repair.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Forme fruste Barlow disease</strong> – This is an intermediate form between classic and nonclassic disease.</p><p></p><p class="headingAnchor" id="H3808113194"><span class="h2">Secondary MVP associated with connective tissue disorders</span><span class="headingEndMark"> — </span>MVP is more prevalent in patients with Marfan syndrome, MASS phenotype (associated with MVP and myopia, as well as aorta, skin, and skeletal features), Ehlers–Danlos syndrome, osteogenesis imperfecta, and pseudoxanthoma elasticum [<a href="#rid22">22,37</a>]. Among patients with Marfan syndrome, mitral valve prolapse occurs more frequently in patients with <em>FBN1</em> mutations as compared with those with <em>TGFBR2</em> mutations (eg, 45 and 21 percent [<a href="#rid38">38</a>]). (See  <a class="medical medical_review" href="/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a>.)</p><p class="headingAnchor" id="H1252548379"><span class="h2">Secondary MVP associated with congenital heart disease</span><span class="headingEndMark"> — </span>MVP has also been found in as many as 15 percent of patients with Ebstein anomaly [<a href="#rid39">39</a>]. This suggests a role for LV deformation in creating mitral imbalance and prolapse despite a structurally normal mitral valve. (See  <a class="medical medical_review" href="/d/html/8146.html" rel="external">"Ebstein anomaly: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H1814760916"><span class="h2">Flail leaflet without myxomatous degeneration</span><span class="headingEndMark"> — </span>A number of other diseases are associated with imbalance of the mitral valve complex, leading to prolapse and flail of the mitral valve. Infective endocarditis causes destructive lesions, and ruptured chordae may ensue, leading to flail mitral leaflet(s).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocardial infarction</strong> – Myocardial ischemia is not a cause of MVP, but myocardial infarction with papillary muscle rupture causes one or both leaflets to prolapse in the left atrium, often with a muscle tip attached.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trauma</strong> – Similarly, blunt chest trauma with rupture of chordae or papillary muscle can cause a flail mitral leaflet.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute rheumatic fever</strong> – This may cause prolapse by true elongation of the valvular tissue, but subsequent tissue retraction makes the occurrence of prolapse due to chronic rheumatic heart disease exceptional unless there is a ruptured chord.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of ruptured chordae</strong> – Other diseases, such as hypertrophic cardiomyopathy, myxomas, or prominent mitral annular calcifications, may also cause ruptured chordae and thereby cause leaflet prolapse. While MR in these cases is technically due to leaflet prolapse, the diagnosis is usually obvious from the clinical presentation and echocardiographic findings, and not associated with myxomatous degeneration of the leaflets.</p><p></p><p class="headingAnchor" id="H1714159851"><span class="h2">By severity</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity of prolapse</strong> – MVP is classified by severity of the abnormal movement of the valve. The leaflets are described as billowing when the tips of leaflets remain in the LV, versus flail when the tip(s) of one (or both) leaflets prolapses into the left atrium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity of MR</strong> – The degree of MR accompanying MVP can range from none, trivial, or mild to progressive (moderate) to severe  (<a class="graphic graphic_table graphicRef95916" href="/d/graphic/95916.html" rel="external">table 2</a>). Quantification of the severity of MR associated with MVP is essential for clinical decision making [<a href="#rid40">40</a>]. (See <a class="local">'Staging MR'</a> below and  <a class="medical medical_review" href="/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation", section on 'Identifying the severity of MR'</a>.)</p><p></p><p class="headingAnchor" id="H28356921"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Anatomically, the mitral valve is formed by a long and narrow anterior leaflet and a shorter and wider posterior leaflet occupying a larger portion of the annular circumference  (<a class="graphic graphic_figure graphicRef83654" href="/d/graphic/83654.html" rel="external">figure 2</a>). Thus, when the mitral valve is closed, it appears from the atrial side as the "mitral smile" with two leaflets and two commissures (anterolateral and posteromedial). The leaflets' bases are attached to the annulus and their tips to the chordae, which join the papillary muscles.</p><p>In both primary MVP and secondary MVP associated with connective tissue disorders, the pathologic process may involve the entire mitral valvular complex (leaflets, chordae, mitral annulus). The hallmark macroscopic valvular lesion of MVP is excessive mitral leaflet tissue leading to folding and hooding affecting one or more segments of one or both leaflets [<a href="#rid41">41,42</a>]. The chordae are elongated, have reduced strength, and may rupture [<a href="#rid43">43</a>]. The annulus is typically dilated and frequently separated from its normal myocardial support [<a href="#rid44">44</a>], causing annular expansion in systole which further accentuates the mitral regurgitation (MR). In contrast, the papillary muscles are usually normal in structure. Thus, MVP is physiologically heterogeneous, with various combinations of leaflet, chordal, and annular alterations yielding insufficient leaflet apposition, resulting in MR.</p><p>Histologically, the characteristic myxomatous lesion is proliferation of the spongiosa of the mitral valve leaflets, with mucopolysaccharide deposits and excessive water content causing leaflet thickening and redundancy. The collagen composition is altered, with a marked increase in type III collagen [<a href="#rid42">42</a>]; elastin fibers appear fragmented [<a href="#rid43">43</a>]. Focal accumulation of activated valvular interstitial cells and increased expression of matrix metalloproteinases suggest that abnormal tissue remodeling is responsible for the disease [<a href="#rid45">45</a>].</p><p>Qualitative histologic analysis cannot differentiate between diffuse myxomatous disease and fibroelastic deficiency [<a href="#rid46">46</a>]. However, a more elaborate semiquantitative analysis shows different patterns, with more myxomatous infiltration, collagen proliferation, and elastic fiber lesions with diffuse myxomatous disease and Marfan syndrome than in fibroelastic deficiency. (See <a class="local">'Morphology of primary MVP'</a> above.)</p><p class="headingAnchor" id="H28356936"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Symptoms are most often absent or mild but, if present, are nonspecific for MVP [<a href="#rid47">47</a>]. Most patients are diagnosed based on auscultatory findings that lead to evaluation by echocardiography or on echocardiography ordered for other unrelated reasons.</p><p class="headingAnchor" id="H2471468409"><span class="h2">MVP syndrome</span><span class="headingEndMark"> — </span>MVP syndrome is a term previously used to describe a constellation of symptoms and conditions associated with MVP including chest pain, palpitations, dyspnea, exercise intolerance, dizziness, lean body habitus, and anxiety disorders [<a href="#rid7">7,48</a>]. However, many reports of associations were limited by inadequate control groups and use of older, insufficiently stringent diagnostic criteria for MVP (see <a class="local">'Imaging definition of MVP'</a> below). Among the previously reported clinical correlates of MVP, only the association with lower body mass index than controls has been reproducibly associated with MVP [<a href="#rid7">7,48,49</a>]. </p><p>A study comparing 281 individuals with MVP with 65 individuals without MVP found that presence of MVP was not independently associated with psychoemotional status [<a href="#rid49">49</a>].</p><p>While posttraumatic stress disorder (PTSD) was prevalent in a population of 186 patients with moderate to severe DMR (23 versus 9 percent of age-matched controls), the risk of PTSD was not associated with MR severity [<a href="#rid50">50</a>]. A prospective study found that psychoemotional status and health-related quality of life were commonly impaired in 131 patients with severe MR prior to mitral surgery [<a href="#rid51">51</a>]. Psychoemotional and health-related quality of life scores normalized at six-month follow-up after mitral surgery.</p><p class="headingAnchor" id="H28356943"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Most patients with MVP are asymptomatic. Symptoms in patients with MVP usually are due either to significant mitral regurgitation (MR) or to a cardiac arrhythmia.</p><p>The majority of patients with MVP (approximately 75 percent) have mild, trace, or no MR; severe MR is uncommon (occurring in approximately 4 percent) [<a href="#rid1">1</a>]. Severe MR can cause heart failure with associated dyspnea and fatigue or may cause asymptomatic progressive LV enlargement.</p><p>Some patients with MVP develop atrial fibrillation or other arrhythmias and present with palpitations. MVP is associated with a risk of ventricular arrhythmias and sudden cardiac death, although the risk of such arrhythmias in most patients with MVP is low.</p><p>MVP may first be diagnosed in a patient with endocarditis who presents with fever and bacteremia [<a href="#rid52">52</a>]. (See <a class="local">'Complications'</a> below.)</p><p class="headingAnchor" id="H28356962"><span class="h2">Physical examination</span></p><p class="headingAnchor" id="H406806"><span class="h3">Cardiac examination</span><span class="headingEndMark"> — </span>The most common auscultatory features of mitral valve prolapse are the nonejection click (single or multiple) and the murmur of MR. The click is thought to be caused by snapping of the mitral chordae during systole when the valve bows into the atrium. The click is mobile, meaning its timing varies with maneuvers that change the LV volume, occurring earlier in systole with sitting, standing, or other interventions that reduce ventricular size, or later with those interventions that increase chamber size such as squatting  (<a class="graphic graphic_movie graphicRef57858" href="/d/graphic/57858.html" rel="external">movie 4</a> and <a class="graphic graphic_movie graphicRef80360" href="/d/graphic/80360.html" rel="external">movie 5</a>) [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/1079.html" rel="external">"Auscultation of heart sounds", section on 'Midsystolic click'</a>.)</p><p>Some patients with MVP have tricuspid valve prolapse, which also produces a midsystolic click. The interval between S1 and the tricuspid valve click generally increases following inspiration or raising the legs or other maneuvers that increase right ventricular volume. (See  <a class="medical medical_review" href="/d/html/1079.html" rel="external">"Auscultation of heart sounds", section on 'Midsystolic click'</a>.)</p><p>When present, the murmur of MR with MVP is late-systolic, particularly early in the disease course. The position of maximal intensity and radiation pattern vary with the direction of the jet (anteriorly-directed jets can be heard over the entire precordial area, while posteriorly directed jets are typically best heard at the apex and radiate towards the axilla and the back). With severe prolapse or a flail leaflet, the murmur is holosystolic and indistinguishable in pitch from other causes of MR, but often will remain maximum at mid-late systole. With long-standing severe MR, the LV apical impulse is displaced laterally, and clinical findings of LV dysfunction (gallop sounds) and pulmonary hypertension (loud P2 component) may be present. (See  <a class="medical medical_review" href="/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a> and  <a class="medical medical_review" href="/d/html/1080.html" rel="external">"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds"</a>.)</p><p>With acute severe MR (as may result from chordal rupture), the cardiac impulse is hyperdynamic but normal in location unless there has been preceding chronic MR. The murmur of acute MR with acute chordal rupture of MVP may be early systolic, midsystolic, or holosystolic and is generally loud due to hyperdynamic LV function, ending before A2. (See  <a class="medical medical_review" href="/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a>.)</p><p>Limited data are available on the diagnostic accuracy of auscultation for MVP, particularly when limited to studies using current echocardiographic diagnostic criteria. Identification of a mobile systolic click by an expert observer may be a highly sensitive finding (88 and 100 percent) with fair specificity (66 and 73 percent) [<a href="#rid54">54,55</a>]. In contrast, in a study of 147 patients referred for echocardiography for suspected MVP, identification of a systolic click by a referring clinician had a sensitivity of 52 percent and specificity of 68 percent for MVP [<a href="#rid56">56</a>]. Of note, auscultatory manifestations are highly variable [<a href="#rid53">53</a>]. This, together with inconsistent clinical examination skills among clinicians and variable auscultatory and echocardiographic criteria used to diagnose MVP, likely explains the conflicting observations on the accuracy of auscultatory findings in MVP.</p><p class="headingAnchor" id="H884133734"><span class="h3">General examination</span><span class="headingEndMark"> — </span>Observation of the general appearance and body habitus is usually the first step in the physical examination. In most patients with MVP, the general examination reveals no specific findings suggestive of MVP. Patients with MVP tend to have a lower body mass index than controls [<a href="#rid7">7,8</a>].</p><p>Some patients with primary MVP have noncardiac findings ("syndromic MVP") including skeletal abnormalities and/or other findings of connective tissue disorders. Skeletal abnormalities associated with MVP include narrow anteroposterior chest diameter, scoliosis and loss of kyphosis of the thoracic spine, and pectus excavatum deformity, although the data on the frequency of these abnormalities in patients with MVP are limited [<a href="#rid17">17,30,57</a>].</p><p>Other physical findings are observed in patients with secondary MVP with connective tissue disorders or other causes of mitral valve disease. (See <a class="local">'Secondary MVP associated with connective tissue disorders'</a> above and <a class="local">'Flail leaflet without myxomatous degeneration'</a> above.)</p><p class="headingAnchor" id="H2899781497"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Additional clinical findings are caused by complications of MVP including severe MR (with chronic, acute, or subacute presentation), infective endocarditis (which may be accompanied by worsening MR), and arrhythmias. (See  <a class="medical medical_review" href="/d/html/8169.html" rel="external">"Mitral valve prolapse: Overview of complications and their management"</a>.)</p><p>As discussed separately, a potential association between MVP and stroke or transient ischemic attack has been explored, but a causal relationship has not been established. (See  <a class="medical medical_review" href="/d/html/8169.html" rel="external">"Mitral valve prolapse: Overview of complications and their management", section on 'Ischemic neurologic events'</a>.)</p><p class="headingAnchor" id="H3448093785"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H3988413744"><span class="h2">General approach</span><span class="headingEndMark"> — </span>MVP should be suspected in patients with a nonejection click (single or multiple) with or without a systolic murmur of mitral regurgitation (MR). Evaluation for MVP is also indicated for adults with one or more first-degree relatives with MVP. Given the time course of development and progression of MVP and MR, these may develop later in life though absent during youth.</p><p>All patients with known or suspected valvular heart disease should undergo careful history, physical examination, and transthoracic echocardiogram (TTE) [<a href="#rid4">4,5</a>].</p><p>Diagnostic evaluation for patients with MVP and a suspected connective tissue disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders", section on 'Diagnosis of MFS'</a> and  <a class="medical medical_review" href="/d/html/14920.html" rel="external">"Clinical manifestations and diagnosis of Ehlers-Danlos syndromes"</a>.)</p><p class="headingAnchor" id="H2305730204"><span class="h2">Echocardiography</span><span class="headingEndMark"> — </span>MVP is diagnosed on TTE, although transesophageal echocardiographic (TEE) imaging may be needed in certain situations (eg, inadequate acoustic windows on TTE). Echocardiography provides information not only about the presence (or absence) of MVP but also allows a comprehensive evaluation of the subvalvular structures, assessment of MR, and identification of hemodynamic consequences.</p><p>Two-dimensional and three-dimensional TEE are important for planning for transcatheter or surgical intervention, as discussed separately. (See  <a class="medical medical_review" href="/d/html/99943.html" rel="external">"Transcatheter edge-to-edge mitral repair", section on 'Preprocedural evaluation'</a>.)</p><p class="headingAnchor" id="H1980804232"><span class="h3">Imaging definition of MVP</span><span class="headingEndMark"> — </span>The current imaging definition of MVP is systolic billowing of any portion of one or both mitral leaflets ≥2 mm above the annular plane into the left atrium in a long-axis view (parasternal or apical three-chamber)  (<a class="graphic graphic_diagnosticimage graphicRef83594" href="/d/graphic/83594.html" rel="external">image 1</a>) [<a href="#rid6">6</a>]. Two-dimensional features associated with MVP are disruption or elongation of mitral leaflets, chordae, or papillary muscles, and enlargement of the annular diameter.</p><p>The abnormal movement of MVP has been challenging to define given the saddle shape of the mitral annulus, which is accentuated in systole due to displacement of the annulus at the commissures towards the ventricular apex [<a href="#rid58">58,59</a>]. Thus, in the apical four-chamber view, the leaflets may appear posterior to the annulus, even in healthy subjects [<a href="#rid60">60,61</a>]. These observations, published in the late 1980s, led to a change in the accepted echocardiographic view for identification of MVP from "any view" to "a (three-chamber) long-axis view."</p><p>Simple override of the anterior leaflet (ie, the anterior leaflet passing behind the posterior leaflet in systole without crossing the annulus plane as commonly seen in ischemic MR due to tethering of the posterior mitral leaflet) should be distinguished from MVP, as management of this condition differs from that for MVP.</p><p>Since diagnostic criteria for MVP have evolved, the literature on MVP must be reviewed with care. Many studies of MVP have design flaws due to inadequate controls and/or insufficiently stringent criteria for MVP. In addition, patients previously misdiagnosed with MVP require appropriate evaluation and counseling.</p><p class="headingAnchor" id="H95681540"><span class="h3">M-mode not used</span><span class="headingEndMark"> — </span>M-mode echocardiography should no longer be used in making a diagnosis of MVP. Previously used M-mode criteria for MVP are not reliable because the normal motion of the base of the heart can either mask or mimic true prolapse.</p><p class="headingAnchor" id="H1915196773"><span class="h3">Staging MR</span><span class="headingEndMark"> — </span>Doppler echocardiographic techniques are used to quantitatively assess MR, but the eccentric nature of the MR jet can make this assessment difficult  (<a class="graphic graphic_table graphicRef95916" href="/d/graphic/95916.html" rel="external">table 2</a>). It is important to quantify the severity of MR, as discussed separately . (See  <a class="medical medical_review" href="/d/html/5334.html" rel="external">"Echocardiographic evaluation of the mitral valve"</a> and  <a class="medical medical_review" href="/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation", section on 'Identifying the severity of MR'</a>.)</p><p>MR severity should be quantified in all patients with a visual appearance of greater than mild MR on color Doppler to guide assessment of prognosis and management. Quantification includes determination of the effective regurgitant orifice area (EROA) and the regurgitant volume. Quantitative measures of MR are essential predictors of outcome [<a href="#rid62">62</a>], as confirmed in large independent prospective studies [<a href="#rid63">63,64</a>], including in routine clinical practice [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/5334.html" rel="external">"Echocardiographic evaluation of the mitral valve", section on 'Quantitative parameters of mitral regurgitation'</a> and  <a class="medical medical_review" href="/d/html/8162.html" rel="external">"Natural history of chronic mitral regurgitation caused by mitral valve prolapse and flail mitral leaflet"</a>.)</p><p>It is important to distinguish mid-late (partial) systolic MR (which is generally associated with benign outcomes) from holosystolic MR. Leaflet malcoaptation limited to mid to late systole causes partial systolic MR [<a href="#rid65">65</a>]. With mid-late systolic MR, regurgitation severity will be overestimated based on EROA and jet area; regurgitant volume more accurately measures disease severity.</p><p class="headingAnchor" id="H2291553106"><span class="h3">Mitral annular disjunction</span><span class="headingEndMark"> — </span>Mitral annular disjunction (MAD) is characterized by systolic separation of the mitral annulus supporting the posterior leaflet from the ventricular myocardium [<a href="#rid66">66</a>]. The posterior mitral leaflet is attached directly to the atrial wall. If the echocardiogram image quality is suboptimal for assessment of MAD, MAD may be assessed by CMR imaging. MAD diagnosis requires dynamic evaluation of the mitral annulus throughout the cardiac cycle (by echocardiography or CMR). The significance of MAD as a potential marker of arrhythmic risk has been debated, as discussed separately. (See  <a class="medical medical_review" href="/d/html/8169.html" rel="external">"Mitral valve prolapse: Overview of complications and their management", section on 'Clinical features associated with ventricular arrhythmias or SCD'</a> and <a class="local">'Cardiovascular magnetic resonance'</a> below.)</p><p class="headingAnchor" id="H407085"><span class="h2">Other imaging</span></p><p class="headingAnchor" id="H28357101"><span class="h3">Cardiovascular magnetic resonance</span><span class="headingEndMark"> — </span>When quantification of MR by echocardiography is uncertain, CMR imaging enables accurate quantification [<a href="#rid4">4</a>]. CMR is indicated when the echocardiogram is technically suboptimal for assessment of MVP (including leaflet length and thickness), MR quantification, MAD, and/or left or right ventricular function.</p><p>In addition, CMR enables detection of focal late gadolinium enhancement of mitral valve leaflets and papillary muscles [<a href="#rid67">67</a>]. Studies have shown that the occurrence of ventricular arrhythmias is also associated with mitral annular disjunction diagnosed by CMR [<a href="#rid68">68</a>], as well as ventricular fibrosis diagnosed by late gadolinium enhancement [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/8169.html" rel="external">"Mitral valve prolapse: Overview of complications and their management", section on 'Risk stratification for SCD and ventricular arrhythmias'</a> and  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging"</a>.)</p><p class="headingAnchor" id="H28357115"><span class="h3">Left ventricular angiography</span><span class="headingEndMark"> — </span>Angiography is not used to diagnose MVP. However, in some patients referred for cardiac catheterization, MVP may be incidentally found on LV angiography, showing the displacement of the mitral valve leaflets into the left atrium with late systolic MR. These patients should be further evaluated by echocardiography. In addition, hemodynamic catheterization and LV angiography are used for assessment of MR severity in patients with discordant clinical and echocardiographic findings. (See  <a class="medical medical_review" href="/d/html/8127.html" rel="external">"Hemodynamics of valvular disorders as measured by cardiac catheterization", section on 'Chronic mitral regurgitation'</a> and  <a class="medical medical_review" href="/d/html/8127.html" rel="external">"Hemodynamics of valvular disorders as measured by cardiac catheterization", section on 'Acute mitral regurgitation'</a>.)</p><p class="headingAnchor" id="H21670405"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The midsystolic click of MVP should be differentiated from other systolic sounds such as aortic or pulmonary ejection clicks (occurring early in systole, at the foot of the carotid upstroke) and from other cardiac sounds (split first or second heart sounds, pericardial sounds, atrial septal aneurysm clicks). A midsystolic click may be confirmed by maneuvers that alter the timing of the sound, as described separately. (See  <a class="medical medical_review" href="/d/html/1079.html" rel="external">"Auscultation of heart sounds", section on 'Midsystolic click'</a>.)</p><p>Echocardiography accurately distinguishes MVP from other causes of systolic sounds as well as from other causes of mitral regurgitation. (See  <a class="medical medical_review" href="/d/html/1079.html" rel="external">"Auscultation of heart sounds", section on 'Nonejection systolic sounds'</a> and  <a class="medical medical_review" href="/d/html/1079.html" rel="external">"Auscultation of heart sounds", section on 'Ejection sounds'</a> and  <a class="medical medical_review" href="/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation", section on 'Identifying the cause of MR'</a> and  <a class="medical medical_review" href="/d/html/8170.html" rel="external">"Acute mitral regurgitation in adults", section on 'Echocardiography'</a>.)</p><p>MVP with myxomatous disease should be differentiated from other causes of flail mitral valve leaflet, as discussed above. (See <a class="local">'Flail leaflet without myxomatous degeneration'</a> above.)</p><p class="headingAnchor" id="H2844273126"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a>.)</p><p class="headingAnchor" id="H25803265"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83799.html" rel="external">"Patient education: Mitral valve prolapse (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28357141"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – The prevalence of mitral valve prolapse (MVP) in the general population is estimated to be 0.6 to 3 percent. This estimate is significantly lower than previously reported due to the current use of a more stringent definition of MVP. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – MVP is classified as either primary (caused by degenerative disease in the absence of an identifiable connective tissue disease; may be sporadic or familial) or secondary (associated with an identifiable disorder such as Marfan syndrome or infective endocarditis)  (<a class="graphic graphic_table graphicRef83655" href="/d/graphic/83655.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">The morphology of primary MVP is classified as either classic (with markedly and diffusely thickened leaflets [≥5 mm] with bileaflet prolapse) or nonclassic (with limited or absent leaflet thickening [thickness &lt;5 mm] and segmental prolapse)  (<a class="graphic graphic_figure graphicRef83595" href="/d/graphic/83595.html" rel="external">figure 1</a>). (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – MVP is widely heterogeneous in its presentation and outcome. Most patients with MVP have no associated symptoms. Most patients with MVP have mild, trace, or no mitral regurgitation (MR); severe MR occurs in approximately 4 percent and may or may not be associated with symptoms. (See <a class="local">'Symptoms'</a> above.)</p><p></p><p class="bulletIndent1">Symptoms related to MVP are caused by complications such as dyspnea and fatigue caused by severe MR with associated heart failure, fever caused by infective endocarditis, and palpitations caused by atrial or ventricular arrhythmias. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect MVP</strong> – MVP should be suspected in patients with a nonejection click (single or multiple) with or without a late systolic or holosystolic murmur of MR  (<a class="graphic graphic_movie graphicRef57858" href="/d/graphic/57858.html" rel="external">movie 4</a> and <a class="graphic graphic_movie graphicRef80360" href="/d/graphic/80360.html" rel="external">movie 5</a>). Evaluation for MVP is also indicated for patients with a family history of MVP. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – MVP is diagnosed by transthoracic echocardiography. MVP is defined as systolic mitral leaflet displacement ≥2 mm above the annular plane in the parasternal or apical long-axis (three-chamber) views  (<a class="graphic graphic_diagnosticimage graphicRef83594" href="/d/graphic/83594.html" rel="external">image 1</a>). (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Imaging definition of MVP'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quantification of MR</strong> – Formal quantification of MR severity (including regurgitant volume and regurgitant orifice area) is indicated in all patients with MVP and more than mild MR, as this guides management and assessment of prognosis. (See <a class="local">'Staging MR'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Freed LA, Benjamin EJ, Levy D, et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J Am Coll Cardiol 2002; 40:1298.</a></li><li><a class="nounderline abstract_t">Dziadzko V, Dziadzko M, Medina-Inojosa JR, et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome. Eur Heart J 2019; 40:2194.</a></li><li><a class="nounderline abstract_t">Luxereau P, Dorent R, De Gevigney G, et al. Aetiology of surgically treated mitral regurgitation. Eur Heart J 1991; 12 Suppl B:2.</a></li><li><a class="nounderline abstract_t">Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.</a></li><li><a class="nounderline abstract_t">Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43:561.</a></li><li><a class="nounderline abstract_t">Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.</a></li><li><a class="nounderline abstract_t">Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341:1.</a></li><li><a class="nounderline abstract_t">Flack JM, Kvasnicka JH, Gardin JM, et al. Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study. Am Heart J 1999; 138:486.</a></li><li><a class="nounderline abstract_t">Theal M, Sleik K, Anand S, et al. Prevalence of mitral valve prolapse in ethnic groups. Can J Cardiol 2004; 20:511.</a></li><li><a class="nounderline abstract_t">Liu PY, Tsai KZ, Lin YP, et al. Prevalence and characteristics of mitral valve prolapse in military young adults in Taiwan of the CHIEF Heart Study. Sci Rep 2021; 11:2719.</a></li><li><a class="nounderline abstract_t">Delling FN, Rong J, Larson MG, et al. Evolution of Mitral Valve Prolapse: Insights From the Framingham Heart Study. Circulation 2016; 133:1688.</a></li><li><a class="nounderline abstract_t">Enriquez-Sarano M, Basmadjian AJ, Rossi A, et al. Progression of mitral regurgitation: a prospective Doppler echocardiographic study. J Am Coll Cardiol 1999; 34:1137.</a></li><li><a class="nounderline abstract_t">Avierinos JF, Gersh BJ, Melton LJ 3rd, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002; 106:1355.</a></li><li><a class="nounderline abstract_t">Procacci PM, Savran SV, Schreiter SL, Bryson AL. Prevalence of clinical mitral-valve prolapse in 1169 young women. N Engl J Med 1976; 294:1086.</a></li><li><a class="nounderline abstract_t">Darsee JR, Mikolich JR, Nicoloff NB, Lesser LE. Prevalence of mitral valve prolapse in presumably healthy young men. Circulation 1979; 59:619.</a></li><li><a class="nounderline abstract_t">Hickey AJ, Wolfers J, Wilcken DE. Mitral-valve prolapse: prevalence in an Australian population. Med J Aust 1981; 1:31.</a></li><li><a class="nounderline abstract_t">Kelly RE, Goretsky MJ, Obermeyer R, et al. Twenty-one years of experience with minimally invasive repair of pectus excavatum by the Nuss procedure in 1215 patients. Ann Surg 2010; 252:1072.</a></li><li><a class="nounderline abstract_t">Pickering NJ, Brody JI, Barrett MJ. von Willebrand syndromes and mitral-valve prolapse; linked mesenchymal dysplasias. N Engl J Med 1981; 305:131.</a></li><li><a class="nounderline abstract_t">Le Tourneau T, Mérot J, Rimbert A, et al. Genetics of syndromic and non-syndromic mitral valve prolapse. Heart 2018; 104:978.</a></li><li><a class="nounderline abstract_t">Delling FN, Rong J, Larson MG, et al. Familial clustering of mitral valve prolapse in the community. Circulation 2015; 131:263.</a></li><li><a class="nounderline abstract_t">Hiemstra YL, Wijngaarden ALV, Bos MW, et al. Familial occurrence of mitral regurgitation in patients with mitral valve prolapse undergoing mitral valve surgery. Eur J Prev Cardiol 2020; 27:272.</a></li><li><a class="nounderline abstract_t">Grau JB, Pirelli L, Yu PJ, et al. The genetics of mitral valve prolapse. Clin Genet 2007; 72:288.</a></li><li><a class="nounderline abstract_t">Roselli C, Yu M, Nauffal V, et al. Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse. Eur Heart J 2022; 43:1668.</a></li><li><a class="nounderline abstract_t">Strahan NV, Murphy EA, Fortuin NJ, et al. Inheritance of the mitral valve prolapse syndrome. Discussion of a three-dimensional penetrance model. Am J Med 1983; 74:967.</a></li><li><a class="nounderline abstract_t">Scheele W, Allen HN, Kraus R, et al. Familial prevalence and genetic transmission of mitral valve prolapse. Circulation 1977; 56 (Suppl. 3):111.</a></li><li><a class="nounderline abstract_t">Monteleone PL, Fagan LF. Possible X-linked congenital heart disease. Circulation 1969; 39:611.</a></li><li><a class="nounderline abstract_t">Lardeux A, Kyndt F, Lecointe S, et al. Filamin-a-related myxomatous mitral valve dystrophy: genetic, echocardiographic and functional aspects. J Cardiovasc Transl Res 2011; 4:748.</a></li><li><a class="nounderline abstract_t">Guta AC, El-Tallawi KC, Nguyen DT, et al. Prevalence and Clinical Implications of Tricuspid Valve Prolapse Based on Magnetic Resonance Diagnostic Criteria. J Am Coll Cardiol 2023.</a></li><li><a class="nounderline abstract_t">Padang R, Enriquez-Sarano M, Pislaru SV, et al. Coexistent bicuspid aortic valve and mitral valve prolapse: epidemiology, phenotypic spectrum, and clinical implications. Eur Heart J Cardiovasc Imaging 2019; 20:677.</a></li><li><a class="nounderline abstract_t">Bon Tempo CP, Ronan JA Jr, de Leon AC Jr, Twigg HL. Radiographic appearance of the thorax in systolic click-late systolic murmur syndrome. Am J Cardiol 1975; 36:27.</a></li><li><a class="nounderline abstract_t">Rosenberg CA, Derman GH, Grabb WC, Buda AJ. Hypomastia and mitral-valve prolapse. Evidence of a linked embryologic and mesenchymal dysplasia. N Engl J Med 1983; 309:1230.</a></li><li class="breakAll">Adams DH, Carabello BA, Castillo J. Mitral valve regurgitation. In: Hurst's The Heart, 13th ed, Fuster V, Walsh RA, Harrington RA (Eds), McGraw-Hill, New York 2010.</li><li><a class="nounderline abstract_t">Eriksson MJ, Bitkover CY, Omran AS, et al. Mitral annular disjunction in advanced myxomatous mitral valve disease: echocardiographic detection and surgical correction. J Am Soc Echocardiogr 2005; 18:1014.</a></li><li><a class="nounderline abstract_t">Essayagh B, Sabbag A, Antoine C, et al. The Mitral Annular Disjunction of Mitral Valve Prolapse: Presentation and Outcome. JACC Cardiovasc Imaging 2021; 14:2073.</a></li><li><a class="nounderline abstract_t">Carpentier A, Lacour-Gayet F, Camilleri J, et al. Fibroelastic dysplasia of the mitral valve. An anatomical clinical entity. Circulation 1980; 62 (Suppl. III):111.</a></li><li><a class="nounderline abstract_t">Mantovani F, Clavel MA, Vatury O, et al. Cleft-like indentations in myxomatous mitral valves by three-dimensional echocardiographic imaging. Heart 2015; 101:1111.</a></li><li><a class="nounderline abstract_t">Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. JAMA 1989; 262:523.</a></li><li><a class="nounderline abstract_t">Attias D, Stheneur C, Roy C, et al. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation 2009; 120:2541.</a></li><li><a class="nounderline abstract_t">Attenhofer Jost CH, Connolly HM, O'Leary PW, et al. Left heart lesions in patients with Ebstein anomaly. Mayo Clin Proc 2005; 80:361.</a></li><li><a class="nounderline abstract_t">Antoine C, Benfari G, Michelena HI, et al. Clinical Outcome of Degenerative Mitral Regurgitation: Critical Importance of Echocardiographic Quantitative Assessment in Routine Practice. Circulation 2018; 138:1317.</a></li><li><a class="nounderline abstract_t">Lucas RV Jr, Edwards JE. The floppy mitral valve. Curr Probl Cardiol 1982; 7:1.</a></li><li><a class="nounderline abstract_t">Cole WG, Chan D, Hickey AJ, Wilcken DE. Collagen composition of normal and myxomatous human mitral heart valves. Biochem J 1984; 219:451.</a></li><li><a class="nounderline abstract_t">Barber JE, Kasper FK, Ratliff NB, et al. Mechanical properties of myxomatous mitral valves. J Thorac Cardiovasc Surg 2001; 122:955.</a></li><li><a class="nounderline abstract_t">Essayagh B, Mantovani F, Benfari G, et al. Mitral Annular Disjunction of Degenerative Mitral Regurgitation: Three-Dimensional Evaluation and Implications for Mitral Repair. J Am Soc Echocardiogr 2022; 35:165.</a></li><li><a class="nounderline abstract_t">Prunotto M, Caimmi PP, Bongiovanni M. Cellular pathology of mitral valve prolapse. Cardiovasc Pathol 2010; 19:e113.</a></li><li><a class="nounderline abstract_t">Fornes P, Heudes D, Fuzellier JF, et al. Correlation between clinical and histologic patterns of degenerative mitral valve insufficiency: a histomorphometric study of 130 excised segments. Cardiovasc Pathol 1999; 8:81.</a></li><li><a class="nounderline abstract_t">Morningstar JE, Nieman A, Wang C, et al. Mitral Valve Prolapse and Its Motley Crew-Syndromic Prevalence, Pathophysiology, and Progression of a Common Heart Condition. J Am Heart Assoc 2021; 10:e020919.</a></li><li><a class="nounderline abstract_t">Devereux RB, Kramer-Fox R, Brown WT, et al. Relation between clinical features of the mitral prolapse syndrome and echocardiographically documented mitral valve prolapse. J Am Coll Cardiol 1986; 8:763.</a></li><li><a class="nounderline abstract_t">Bayer-Topilsky T, Suri RM, Topilsky Y, et al. Mitral Valve Prolapse, Psychoemotional Status, and Quality of Life: Prospective Investigation in the Current Era. Am J Med 2016; 129:1100.</a></li><li><a class="nounderline abstract_t">Bayer-Topilsky T, Trenerry MR, Suri R, et al. Psycho-emotional manifestations of valvular heart diseases: prospective assessment in mitral regurgitation. Am J Med 2013; 126:916.</a></li><li><a class="nounderline abstract_t">Bayer-Topilsky T, Suri RM, Topilsky Y, et al. Psychoemotional and quality of life response to mitral operations in patients with mitral regurgitation: a prospective study. Ann Thorac Surg 2015; 99:847.</a></li><li><a class="nounderline abstract_t">Essayagh B, Sabbag A, Antoine C, et al. Presentation and Outcome of Arrhythmic Mitral Valve Prolapse. J Am Coll Cardiol 2020; 76:637.</a></li><li><a class="nounderline abstract_t">Devereux RB, Kramer-Fox R, Kligfield P. Mitral valve prolapse: causes, clinical manifestations, and management. Ann Intern Med 1989; 111:305.</a></li><li><a class="nounderline abstract_t">Barron JT, Manrose DL, Liebson PR. Comparison of auscultation with two-dimensional and Doppler echocardiography in patients with suspected mitral valve prolapse. Clin Cardiol 1988; 11:401.</a></li><li><a class="nounderline abstract_t">Weis AJ, Salcedo EE, Stewart WJ, et al. Anatomic explanation of mobile systolic clicks: implications for the clinical and echocardiographic diagnosis of mitral valve prolapse. Am Heart J 1995; 129:314.</a></li><li><a class="nounderline abstract_t">Heidenreich PA, Bear J, Browner W, Foster E. The clinical impact of echocardiography on antibiotic prophylaxis use in patients with suspected mitral valve prolapse. Am J Med 1997; 102:337.</a></li><li><a class="nounderline abstract_t">Malcolm AD. Mitral valve prolapse associated with other disorders. Casual coincidence, common link, or fundamental genetic disturbance? Br Heart J 1985; 53:353.</a></li><li><a class="nounderline abstract_t">Grewal J, Suri R, Mankad S, et al. Mitral annular dynamics in myxomatous valve disease: new insights with real-time 3-dimensional echocardiography. Circulation 2010; 121:1423.</a></li><li><a class="nounderline abstract_t">Clavel MA, Mantovani F, Malouf J, et al. Dynamic phenotypes of degenerative myxomatous mitral valve disease: quantitative 3-dimensional echocardiographic study. Circ Cardiovasc Imaging 2015; 8.</a></li><li><a class="nounderline abstract_t">Levine RA, Handschumacher MD, Sanfilippo AJ, et al. Three-dimensional echocardiographic reconstruction of the mitral valve, with implications for the diagnosis of mitral valve prolapse. Circulation 1989; 80:589.</a></li><li><a class="nounderline abstract_t">Levine RA, Triulzi MO, Harrigan P, Weyman AE. The relationship of mitral annular shape to the diagnosis of mitral valve prolapse. Circulation 1987; 75:756.</a></li><li><a class="nounderline abstract_t">Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005; 352:875.</a></li><li><a class="nounderline abstract_t">Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol 2009; 54:1099.</a></li><li><a class="nounderline abstract_t">Kang DH, Kim JH, Rim JH, et al. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation 2009; 119:797.</a></li><li><a class="nounderline abstract_t">Topilsky Y, Michelena H, Bichara V, et al. Mitral valve prolapse with mid-late systolic mitral regurgitation: pitfalls of evaluation and clinical outcome compared with holosystolic regurgitation. Circulation 2012; 125:1643.</a></li><li><a class="nounderline abstract_t">Sabbag A, Essayagh B, Barrera JDR, et al. EHRA expert consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex in collaboration with the ESC Council on valvular heart disease and the European Association of Cardiovascular Imaging endorsed cby the Heart Rhythm Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart Rhythm Society. Europace 2022; 24:1981.</a></li><li><a class="nounderline abstract_t">Han Y, Peters DC, Salton CJ, et al. Cardiovascular magnetic resonance characterization of mitral valve prolapse. JACC Cardiovasc Imaging 2008; 1:294.</a></li><li><a class="nounderline abstract_t">Dejgaard LA, Skjølsvik ET, Lie ØH, et al. The Mitral Annulus Disjunction Arrhythmic Syndrome. J Am Coll Cardiol 2018; 72:1600.</a></li><li><a class="nounderline abstract_t">Constant Dit Beaufils AL, Huttin O, Jobbe-Duval A, et al. Replacement Myocardial Fibrosis in Patients With Mitral Valve Prolapse: Relation to Mitral Regurgitation, Ventricular Remodeling, and Arrhythmia. Circulation 2021; 143:1763.</a></li></ol></div><div id="topicVersionRevision">Topic 8172 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12383578" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31121021" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1936017" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aetiology of surgically treated mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332150" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34453165" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2021 ESC/EACTS Guidelines for the management of valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18820172" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10387935" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence and clinical outcome of mitral-valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10467199" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15100753" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence of mitral valve prolapse in ethnic groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33526804" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence and characteristics of mitral valve prolapse in military young adults in Taiwan of the CHIEF Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27006478" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evolution of Mitral Valve Prolapse: Insights From the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10520803" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Progression of mitral regurgitation: a prospective Doppler echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12221052" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Natural history of asymptomatic mitral valve prolapse in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1256525" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence of clinical mitral-valve prolapse in 1169 young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/421301" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence of mitral valve prolapse in presumably healthy young men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7207291" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mitral-valve prolapse: prevalence in an Australian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107118" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Twenty-one years of experience with minimally invasive repair of pectus excavatum by the Nuss procedure in 1215 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6787425" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : von Willebrand syndromes and mitral-valve prolapse; linked mesenchymal dysplasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29352010" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Genetics of syndromic and non-syndromic mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25361552" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Familial clustering of mitral valve prolapse in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31475862" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Familial occurrence of mitral regurgitation in patients with mitral valve prolapse undergoing mitral valve surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17850623" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The genetics of mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35245370" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859065" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inheritance of the mitral valve prolapse syndrome. Discussion of a three-dimensional penetrance model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Familial prevalence and genetic transmission of mitral valve prolapse</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5787314" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Possible X-linked congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21773876" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Filamin-a-related myxomatous mitral valve dystrophy: genetic, echocardiographic and functional aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36813687" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence and Clinical Implications of Tricuspid Valve Prolapse Based on Magnetic Resonance Diagnostic Criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30445616" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Coexistent bicuspid aortic valve and mitral valve prolapse: epidemiology, phenotypic spectrum, and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1146694" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Radiographic appearance of the thorax in systolic click-late systolic murmur syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6633572" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hypomastia and mitral-valve prolapse. Evidence of a linked embryologic and mesenchymal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6633572" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypomastia and mitral-valve prolapse. Evidence of a linked embryologic and mesenchymal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16198877" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mitral annular disjunction in advanced myxomatous mitral valve disease: echocardiographic detection and surgical correction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34147457" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Mitral Annular Disjunction of Mitral Valve Prolapse: Presentation and Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fibroelastic dysplasia of the mitral valve. An anatomical clinical entity</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25935768" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cleft-like indentations in myxomatous mitral valves by three-dimensional echocardiographic imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2739055" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996017" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15757018" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Left heart lesions in patients with Ebstein anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29853518" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical Outcome of Degenerative Mitral Regurgitation: Critical Importance of Echocardiographic Quantitative Assessment in Routine Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7116912" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The floppy mitral valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6430269" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Collagen composition of normal and myxomatous human mitral heart valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11689801" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mechanical properties of myxomatous mitral valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34517112" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mitral Annular Disjunction of Degenerative Mitral Regurgitation: Three-Dimensional Evaluation and Implications for Mitral Repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19375355" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cellular pathology of mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10724505" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Correlation between clinical and histologic patterns of degenerative mitral valve insufficiency: a histomorphometric study of 130 excised segments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34155898" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mitral Valve Prolapse and Its Motley Crew-Syndromic Prevalence, Pathophysiology, and Progression of a Common Heart Condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3760352" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Relation between clinical features of the mitral prolapse syndrome and echocardiographically documented mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27235006" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mitral Valve Prolapse, Psychoemotional Status, and Quality of Life: Prospective Investigation in the Current Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23932160" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Psycho-emotional manifestations of valvular heart diseases: prospective assessment in mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25620595" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Psychoemotional and quality of life response to mitral operations in patients with mitral regurgitation: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32762897" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Presentation and Outcome of Arrhythmic Mitral Valve Prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2667419" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mitral valve prolapse: causes, clinical manifestations, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3396240" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comparison of auscultation with two-dimensional and Doppler echocardiography in patients with suspected mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7832105" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Anatomic explanation of mobile systolic clicks: implications for the clinical and echocardiographic diagnosis of mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217614" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The clinical impact of echocardiography on antibiotic prophylaxis use in patients with suspected mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3885977" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mitral valve prolapse associated with other disorders. Casual coincidence, common link, or fundamental genetic disturbance?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231533" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Mitral annular dynamics in myxomatous valve disease: new insights with real-time 3-dimensional echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25956922" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dynamic phenotypes of degenerative myxomatous mitral valve disease: quantitative 3-dimensional echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2766511" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Three-dimensional echocardiographic reconstruction of the mitral valve, with implications for the diagnosis of mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3829339" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The relationship of mitral annular shape to the diagnosis of mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15745978" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Quantitative determinants of the outcome of asymptomatic mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19744620" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188506" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22388325" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mitral valve prolapse with mid-late systolic mitral regurgitation: pitfalls of evaluation and clinical outcome compared with holosystolic regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35951656" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : EHRA expert consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex in collaboration with the ESC Council on valvular heart disease and the European Association of Cardiovascular Imaging endorsed cby the Heart Rhythm Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19356441" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cardiovascular magnetic resonance characterization of mitral valve prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30261961" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The Mitral Annulus Disjunction Arrhythmic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33706538" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Replacement Myocardial Fibrosis in Patients With Mitral Valve Prolapse: Relation to Mitral Regurgitation, Ventricular Remodeling, and Arrhythmia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
